ISO 13485 Certified
+2 Million Patients treated
Class IIb & Class III Medical Devices
Non Pyrogenic – Sterile
Dedicated Kits for specific preparations
+ 200 published studies
Benefits of PRP therapy
for your patients.
Read the clinical evidence about treatment of tendinopathies and other musculoskeletal disorders.
View the clinical evidence for treatment of scars.
Read the clinical evidence about treatment of knee osteoarthritis.
The Regen Lab technology is based on the use of a thixotropic gel to separate the blood components. This process is protected by many patents (US8529957, EP2073862, US2014010857). Thixotropy is a physical property of some gels. The gel acts as a mechanical separator of the blood components.
Regen Lab Quality System Management ensures the consistency of our products quality in total GMP compliance. Our production facility rooms atmosphere is monitored to satisfy non-pyrogenic medical devices manufacturing.
Categorized as Blog
PRP – Rational/Indication Does current clinical evidence support the use of PRP for knee OA For which degrees of knee OA is PRP best indicated? Can PRP be used in severe knee OA (KL4)? Is PRP indicated for the treatment of Patellofemoral OA (PFOA)? Are there specific contraindications for the use of PRP for knee… Continue reading Home
Categorized as Blog
In April 2022, following the annual ESSKA congress, a group of experts published an important document stating their recommendations on the use of PRP in the management of knee osteoarthritis. This is a consensus paper which was obtained after more than 2 years of deliberations on the subject, answering 28 specific questions for which an… Continue reading Home
Categorized as Latest Global News and Events
Friday 3rd to Sunday 5th June @ Paris Session program coming soon ! More informations
Since 2003, RegenLab® has been committed to the development of a unique expertise in the design and manufacturing of high-quality medical devices, intended for the preparation of cellular therapies and autologous platelet-rich plasma (PRP) from the patient’s own blood. Bringing these technologies to the United States in 2013, RegenLab® USA offers Regen® A-PRP® and Autologous Thrombin Serum with a focus on product quality, patient safety, and preparation efficiency. Now in 2022, RegenLab is proud to be manufactured in the USA. As we look to the future, we are committed to guiding new standards for emerging categories within the field of regenerative medicine.
History: Founded in Switzerland in 2003, Our patient-centered technology has led to over one million treatments provided worldwide using RegenLab® products. In 2017, a new Good Manufacturing Practice (GMP) facility was completed in Mont-sur-Lausanne, Switzerland (canton of Vaud-needed?) allowing RegenLab® to increase access to autologous cellular therapies around the world.
Now is the time to change your patient’s life. Browse ressources and
get connected to treatment that is right for them.
Our Regional offices are